Andrew Dickinson, the Chief Financial Officer of Gilead Sciences Inc (GILD, Financial), sold 5,000 shares of the company on January 16, 2024, according to a recent SEC Filing. Gilead Sciences Inc is a biopharmaceutical company that researches, develops, and commercializes drugs in areas such as HIV/AIDS, liver diseases, hematology and oncology, inflammatory and respiratory diseases, and cardiovascular conditions.
Over the past year, the insider has sold a total of 15,000 shares and has not made any purchases of the company's stock.
The insider transaction history for Gilead Sciences Inc shows a pattern of insider sales, with 0 insider buys and 8 insider sells over the past year.
On the day of the insider's recent sale, shares of Gilead Sciences Inc were trading at $85.78, resulting in a market cap of $107,770,163,000.
The company's price-earnings ratio stands at 18.56, which is lower than the industry median of 23.305 but higher than the company’s historical median price-earnings ratio.
With the current share price of $85.78 and a GuruFocus Value of $72.98, Gilead Sciences Inc has a price-to-GF-Value ratio of 1.18, indicating that the stock is considered Modestly Overvalued according to the GF Value metric.
The GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor related to the company's past performance, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
